Vaxcyte, Inc.
PCVX
$59.71
-$0.66-1.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -284.30M | -320.62M | -246.51M | -212.83M | -166.57M |
| Total Depreciation and Amortization | 5.93M | 5.85M | 9.80M | 5.20M | 4.99M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.23M | 37.05M | 31.58M | 32.25M | 6.73M |
| Change in Net Operating Assets | 673.00K | -2.91M | -19.70M | 32.08M | 33.69M |
| Cash from Operations | -232.47M | -280.63M | -224.83M | -143.31M | -121.17M |
| Capital Expenditure | -4.57M | -14.79M | -8.42M | -12.05M | -9.76M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 152.29M | -218.62M | 123.55M | 133.22M | 87.50M |
| Cash from Investing | 147.72M | -233.41M | 115.13M | 121.17M | 77.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.76M | 610.88M | 3.42M | 306.00K | 3.24M |
| Repurchase of Common Stock | -2.06M | -9.30M | -1.01M | -3.98M | -717.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.70M | 601.58M | 2.41M | -3.67M | 2.52M |
| Foreign Exchange rate Adjustments | 1.40M | -664.00K | 176.00K | 291.00K | 800.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -77.65M | 86.88M | -107.12M | -25.52M | -40.11M |